OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial
OnabotulinumtoxinA effectively reduced the appearance of MMP and improved PROs, with effects lasting up to 6 months and a favorable safety profile.
Authors
- Joan-En Chang-Lin
- Shannon Humphrey (ORCID: https://orcid.org/0000-0002-7734-3146)
- Elisabeth Lee (ORCID: https://orcid.org/0000-0003-3674-9710)
- William McGillivray
- Shu‐Hung Huang (ORCID: https://orcid.org/0000-0002-2903-1703)
- Catherine Foley (ORCID: https://orcid.org/0000-0002-0603-4995)
- Yan Wu (ORCID: https://orcid.org/0000-0003-4625-8560)
- Mitchell F. Brin (ORCID: https://orcid.org/0000-0002-1989-6076)
- Lei Wang (ORCID: https://orcid.org/0000-0002-8811-8489)
- Yuguang Zhang (ORCID: https://orcid.org/0000-0001-7596-2114)
- Jiaming Sun (ORCID: https://orcid.org/0000-0001-8223-0093)
- Shyi-Gen Chen (ORCID: https://orcid.org/0000-0001-6796-8188)
- Beta Bowen
- Vaishali Patel
- Grace Pan
- Donna L Faletto
Institutions
- Tri-Service General Hospital (TW)
- Union Hospital (HK)
- University of British Columbia (CA)
- Kaohsiung Medical University (TW)
- Shanghai Jiao Tong University (CN)
- Peking University (CN)
- Spinal Cord Injury BC (CA)
- AbbVie (United States) (US)
- SKiN Health (CA)
- Plastic Surgery Hospital (CN)
- Shanghai Ninth People's Hospital (CN)
- Wuhan Union Hospital (CN)
- Peking University First Hospital (CN)
- National Defense Medical Center (TW)
Publication Details
- Journal
- Aesthetic Surgery Journal
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1093/asj/sjaf204
- Primary Topic
- Facial Rejuvenation and Surgery Techniques
- Type
- article
- Field-Weighted Citation Impact
- 0.00